Truist Financial Raises Dianthus Therapeutics (NASDAQ:DNTH) Price Target to $128.00

Truist Financial has increased its price target for Dianthus Therapeutics (NASDAQ:DNTH) to $128.00 from $110.00, reiterating a "buy" rating, which suggests an 18.89% upside. This comes amidst a generally positive analyst sentiment for DNTH, with a consensus "Moderate Buy" rating and an average target price of $124.27. Despite missing quarterly earnings estimates and significant insider stock sales totaling $7.99 million, the company's stock recently traded at $107.66.